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Abstract. The aim of this review is to explore the mo-
lecular mechanism and genetic components of the sleep-
wake cycle and insomnia. Moreover, we wanted to re-
view the correlation between primary insomnia and its
comorbidities. With this aim, a systematic review of re-
cent evidence of the molecular and genetic mechanisms
involved in the causation of primary insomnia, along
with associations between primary insomnia and other
diseases were conducted. Primary insomnia is a complex
disorder which accounts for 25% of total chronic insom-
nia and has several effects other than on sleep. It is
manifested by a variety of genetic, cultural, social, psy-
chological and environmental factors. Chronic insom-
nia has been shown to be 24-hour hyperarousal with
reduced relative metabolism in the prefrontal cortex
while awake. Insomnia can cause various physiological
effects and memory capacity alterations; with chronic
activation of the hypothalamic–pituitary–adrenal axis
also leading to the development of depression and anxi-
ety. Orexins and melatonin are important regulators of
sleep and wakefulness. Detailed mechanisms of altera-
tions to the neuroendocrine components highlight the
therapeutic potential of orexin antagonists, as well as
exogenous melatonin and melatonin receptor agonists.
Genetics plays an important role in the development of
insomnia, with several single nucleotide polymorphisms
implicated in sleep regulation. Further research is cru-
cial to aid understanding of this common disorder and
enhance treatment options.
Keywords: Primary Insomnia, Genetics, Orexins,
Melatonin, Insomnia-Related Morbidity
Abbreviations
β-TrCP1: Beta-transducin repeat containing pro-
tein 1; 5-HT: serotonin; 5-HTT: serotonin trans-
porter; 5-HTTLPR: serotonin-transporter-linked poly-
morphic region; ABCC9: ATP-binding cassette, sub-
family C member 9; ATP: adenosine triphosphate;
CACNA1C: Calcium Voltage-Gated Channel Subunit
Alpha1 C; CSF: cerebrospinal fluid; Cry: Crypto-
chrome; CSNK1D: Casein Kinase 1 Delta; CSNK1E:
Casein Kinase 1 Epsilon; DEC2: Differentiated em-
bryo chondrocyte 2; DSM-5: Diagnostic and Stat-
istical Manual of Mental Disorders, Fifth Edition;
EEG: Electroencephalography; Elp3: Elongator com-
plex protein 3; FDA: Food and Drug Administra-
tion; GABA: Gamma-Aminobutyric Acid; HPA: hy-
pothalamic–pituitary–adrenal; LD: light/dark; LH: lat-
eral hypothalamus; nAChR: nicotinic acetylcholine re-
ceptor; NE: norepinephrine; NPS: Neuropeptide S;
NPSR1: neuropeptide S receptor 1; NREM: non-rapid
eye movement; OX1R: Hypocretin (orexin) receptor
type 2; OX2R: Hypocretin (orexin) receptor type 2; Per:
Period; PLCB1: phospholipase C beta 1; REM: rapid
eye movement; ROR: RAR-related orphan receptors;
RORE: retinoic acid related orphan receptor response
element; SCN: suprachiasmatic nucleus; SIRT1: Sirtuin
1; SSS: Sleepless; SUR2: Sulfonylurea receptor 2; SWS:
short wave sleep; VNTR: variable-number tandem re-
peat.
1 Background
Sleep is essential for all humans, contributing to ap-
proximately a third of our lives. Hence, the inability
to sustain good quality and refreshing sleep can have
detrimental effects on individuals. Approximately one-
third of the American population report symptoms of
insomnia (Ancoli-Israel & Roth, 1999), with 10–15% of
the general population meeting the DSM-5 (Diagnostic
and Statistical Manual of Mental Disorders, Fifth Edi-
tion) criteria, thereby making it the most common sleep
complaint. DSM-5 defines insomnia as a syndrome char-
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acterised by problems in one or more of four sleep do-
mains: difficulty initiating sleep, difficulty maintain-
ing sleep, early morning awakening and non-restorative
sleep, which may be associated with impairment in day-
time functioning. The severity of insomnia is dependent
on its frequency, duration and impairment in function-
ing (Ohayon, 1996). As well as the effects on wellbeing,
the direct cost of insomnia alone is estimated to be
around 14 billion dollars annually in the United States
(Walsh & Engelhardt, 1999), with its burden and preval-
ence on the increase (Ford, Cunningham, Giles & Croft,
2015, 3).
Sleep is modulated by a combination of two internal
influences that work partly independent of each other:
the sleep homeostatic mechanism and the circadian
mechanism. The homeostatic drive for sleep is regulated
mainly by adenosine and melatonin, which accumulates
throughout the waking day. The 24-hour rhythms of
the sleep/wake cycle are synchronised to the external
environment, mostly influenced by light (Moore, 2007).
The suprachiasmatic nucleus (SCN) is the main circa-
dian pacemaker of the body, which regulates the circa-
dian oscillators via neural and endocrine control (Moore,
2007) and controls the pineal gland through a neur-
onal pathway (Hardeland, 2013). Light signals activ-
ate the SCN which then inhibit the release of melatonin
from the pineal gland. The light-dark cycle is therefore
important in controlling the circadian rhythm of sleep
(Pandi-Perumal et al., 2007). A decrease in SCN neuron
firing rate, due to less light, allows for an increase in
sympathetic action potential, more norepinephrine (NE)
release on the pineal gland and an increase in melatonin
production. Melatonin, in turn, decreases the activity
of SCN neurons, thus lowering the circadian drive for
arousal in a positive feedback manner (Moore, 2007).
Lesions of the hypothalamus affecting and restricted to
the SCN can result in disruption of the sleep-wake cycle
(Moore, 2007; Pandi-Perumal et al., 2007). The syn-
chronization of the circadian clock is not a completely
hierarchical SCN-driven system. Peripheral clocks may
be regulated independently of the SCN both by light and
other external factors thereby increasing the plasticity
of the circadian system, at even down to the level of cell
to cell communication and paracrine regulation (Duffy
& Czeisler, 2009; Gibbs et al., 2014; Husse, Eichele &
Oster, 2015; Scheer, Wright K. P., Kronauer & Czeisler,
2007).
The aetiology of insomnia is a complex interaction
of genetic, environmental, physiological and behavi-
oural factors. Chronic insomnia leads impaired occu-
pational performance along with a large variety of ser-
ious health complaints (Chevalier et al., 1999). Rather
than solely sleep deprivation, investigations now sug-
gest that insomnia is actually a state of 24-hour hy-
perarousal that causes changes in electroencephalogram
(EEG) recordings, increased night sympathetic activ-
ity, higher adenosine triphosphate (ATP) utilisation
in the grey matter and increased activation of hypo-
thalamic–pituitary–adrenal (HPA) axis, with reduced
relative metabolism in the prefrontal cortex while awake
(Nofzinger et al., 2004). These are consistent with
an alternating daytime cytokine secretion pattern and
hypersecretion in patients with primary insomnia, fur-
ther supported by the alterations to the endocrine and
immune system (Riemann et al., 2007). Long-term
sympathetic hyperactivity is associated with elevated
plasma insulin, a decrease in high density lipoproteins,
an increase in triglyceride, total cholesterol, plasma an-
giotensin, haematocrit, as well as an increase in cardiac
arrhythmias and hypertension. Chronic activation of
the HPA axis can lead to depression, chronic anxiety,
hypertension, visceral obesity, along with various other
pathologies (Vgontzas, Liao, Bixler, Chrousos & Vela-
Bueno, 2009). This highlights the detrimental effect in-
somnia has on the overall health of its sufferers.
2 Insomnia Related Morbidity
Insomnia is an independent factor for increased hospit-
alisation in the general population (Parthasarathy et al.,
2015). An inappropriate amount of habitual sleep may
impact many physiological processes, affecting perform-
ance and both mental and physical health (Sivertsen et
al., 2014).
Insomnia and reduced sleep duration correlate with
an increase in body weight (Gupta, Mueller, Chan &
Meininger, 2002; Kripke, Garfikel, Wingard, Klauber &
Marley, 2002), with individuals who sleep less than five
hours at a greater risk of obesity (Patel et al., 2008).
A high body mass index, in turn, increases the risk
of various cancers, metabolic diseases such as ischemic
stroke, coronary heart disease and type 2 diabetes mel-
litus (WHO, 2014). A decrease in leptin, increase in
ghrelin and body mass index have been associated with
habitual sleep duration of below 7.7 hours a day (Taheri,
Lin, Austin, Young & Mignot, 2004).
Both chronic insomniacs and people who regularly
sleep less than 5 hours a day have been associated with a
three-fold increase in the likelihood of having type 2 dia-
betes mellitus. Insomnia and short sleep duration have
synergistic effects to increase the incidence of diabetes
further (Vgontzas et al., 2009). Impaired glycaemia con-
trol has also been observed in individuals with acute or
short-term modest sleep loss (Mallon, Broman & Hetta,
2005).
Cardiovascular disease is the leading cause of death
in both men and women (Heron, 2012). Various hypo-
theses explain how insomnia and short sleep duration af-
fect the cardiovascular system, ranging from alterations
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in hormone secretion to creating an inflammatory state
(Bansil, Kuklina, Merritt & Yoon, 2011; Vgontzas et al.,
2009). A meta-analysis by Sofi et al. (2014) of thirteen
prospective studies, concluded that subjects who repor-
ted to have difficulty initiating sleep or maintaining sleep
have a 45% increased risk of morbidity and/or mortal-
ity from cardiovascular diseases, compared with normal
sleepers. Hypotheses for this relate to the correlation of
insomnia with metabolic and endocrine changes along
with sympathetic activation and increased cytokine pro-
duction and inflammatory response (Parthasarathy et
al., 2015).
Sleep is vital in the functioning and development of
the brain, including gene expression as well as the pro-
cesses of memory formation and learning. This allows
the cortical plasticity to form long-term memory as well
as synaptic modifications and may explain the strength-
ening of memory traces during sleep (Niethard, Bur-
galossi & Born, 2017). This occurs in the hippocampal-
neocortical networks. In fact, the hippocampus has
shown to be smaller in those suffering from primary
insomnia (Riemann et al., 2007). Long-term potenti-
ation is central for memory and learning and it is known
to be dependent on a prolonged period of sleep with
no interruptions (Kirkpatrick et al., 2017; Niethard et
al., 2017; Rasch & Born, 2013). Five to six hours of
sleep deprivation impairs long-term potentiation main-
tenance, as shown in rat models (Campbell, Guinan &
Horowitz, 2002). The different stages of sleep have been
shown to aid in the processing of different aspects of
memory consolidation and cognitive performance (Nis-
sen et al., 2011). In insomniacs there is reduced improve-
ment in procedural memory across a 12-hour period,
which includes sleep. Declarative memory in particu-
lar is hindered in the individuals suffering from primary
insomnia, compared to normal sleepers (Griessenberger
et al., 2013). The reprocessing of newly acquired in-
formation in the hippocampal and neocortical networks
occurs during slow wave sleep (SWS) or deep sleep and
could be the basis for long-term memory consolidation
(Gais & Born, 2004). During SWS, the acetylcholine in
the hippocampus drops to very low levels, aiding con-
solidation further. Rats that experience limited sleep
have a small hippocampus. Sleep deprivation is related
to lowered cell proliferation and elevated levels of gluco-
corticoids in the bloodstream, which inhibit adult neuro-
genesis (Mirescu, Peters, Noiman & Gould, 2006).
3 The Neuroendocrine Component
3.1 Orexins
Orexin-A and Orexin-B are hypothalamic neuropeptides
involved in wakefulness (de Lecea et al., 1998; Sakurai
et al., 1998). Orexinergic neurons stabilise wakeful-
ness by innervating several nuclei in the brain contain-
ing monoaminergic and cholinergic neurons. The dorso-
medial nucleus of the hypothalamus sends information
about the circadian rhythms and timing of wakefulness
to influence orexin neurons. Orexinergic neurons are
highly active during wakefulness and cease during sleep
(Adamantidis, Zhang, Aravanis, Deisseroth & de Lecea,
2007; Brisbare-Roch et al., 2007; de Lecea & Huerta,
2014; Gotter et al., 2016; Herring et al., 2012). Inappro-
priately activated orexin neurons at night may contrib-
ute to insomnia and cause signs of hyperarousal, such
as increased metabolic rate and sympathetic tone (Bon-
net & Arand, 1998, 2003). When orexin is injected into
rodents, rapid eye movement (REM) and non-rapid eye
movement (NREM) sleep decrease and wakefulness in-
creases. In humans, orexin deficiency is associated with
narcolepsy, while mice develop a phenotype of narco-
lepsy or cataplexy when orexin receptors, OX1R and
OX2R, are knocked out (Chemelli et al., 1999). Thus,
orexin is a master regulator of the sleep-wake cycle, with
high activity of the lateral hypothalamus (LH), cells dur-
ing wake, and a trivial amount in sleep. Locus coer-
uleus noradrenergic, tuberomammillary nucleus histam-
inergic, raphe serotonergic, basal forebrain cholinergic
neurons and pedunculopontine/laterodorsal tegmental
nuclei are all activated to increase wakefulness (Hara et
al., 2001; Hoyer & Jacobson, 2013; Mieda & Sakurai,
2013; Sakurai, 2007).
Orexin-A and orexin-B suppress REM sleep through
G protein-coupled receptors, OX1R and OX2R, by in-
creasing the duration of long waking bouts (Bettica
et al., 2012; Sakurai et al., 1998). OX-A has similar
affinity to OX1R and OX2R, while OX-B has a ten-
fold preferential towards OX2R (Brown, Basheer, McK-
enna, Strecker & McCarley, 2012). During NREM and
REM sleep, orexin neurons are inhibited by GABAer-
gic neurons acting on GABAA and GABAB receptors.
GABAA receptor antagonism increases orexin neurons
during NREM sleep (Alam et al., 2010; Brown et al.,
2012; Li, Gao, Sakurai & van den Pol, 2002; Sergeeva,
Eriksson, Sharonova, Vorobjev & Haas, 2002).
Orexin antagonists block OX2R, or both OX1 and
OX2 receptors, to promote sleep in animals. They spe-
cifically target arousal and thus have fewer side effects
than benzodiazepine receptor agonists, which affect sev-
eral other brain functions (Scammell & Winrow, 2011).
Administration of such antagonists has been found to be
more effective during the wake phase, and is less effect-
ive when administered during the normal sleep period
when orexin activity is low. NREM and REM sleep
are increased in humans whilst wakefulness is decreased
(Brown et al., 2012). Orexin receptor antagonists im-
prove onset and maintenance of sleep without significant
tolerability issues or withdrawal effects in patients with
chronic insomnia (Winrow & Renger, 2014). Narcolepsy
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is, however, a possible side effect of orexin antagon-
ists, with symptoms including hallucinations, cataplexy,
sleep onset REM episodes and sleep paralysis (Mieda &
Sakurai, 2013).
In clinical trials, dual orexin receptor antagonists have
improved sleep latency, increased sleep duration and de-
creased wake after sleep onset (Winrow & Renger, 2014).
Suvorexant is a dual orexin receptor antagonist which
has been found to decrease active wake, time to sleep on-
set and wake after sleep onset, and increase total sleep
time (Hoyer & Jacobson, 2013). Suvorexant is a small
molecular, diazepane-based antagonist which binds to
human OX1R and OX2R with similar potency and in-
hibits by dose-dependent receptor occupancy. It pro-
motes the transition to REM and SWS in animals and
humans (Yin, Mobarec, Kolb & Rosenbaum, 2015), and
increases sleep in rats. Suvorexant reduces sleep on-
set latency for primary insomnia patients, and increases
persistent sleep time. After three months of trials, pa-
tients on daily suvorexant exhibited improved latency
to persistent sleep and wake after sleep onset. Unlike
benzodiazepines, these do not suppress REM sleep, nor
affect memory, and have no claimed following day ef-
fects, unlike GABAA modulators (Hoyer & Jacobson,
2013). There were no serious side effects or next-day re-
sidual effects, and no rebound insomnia on stopping the
drug. No narcolepsy-like symptoms were observed. This
is preferred over benzodiazepine receptor agonists in
chronic primary insomnia since it induces natural sleep
without serious side effects (Mieda & Sakurai, 2013).
SB-649868 is a dual orexin receptor antagonist cur-
rently in development by GlaxoSmithKline, it has been
shown to improve the sleep of healthy individuals dis-
rupted by noise when given in 10 mg or 30 mg doses.
Wake after sleep onset was shown to be reduced with
the 30 mg dose. Thus, it helps both sleep initiation
and maintenance. Number of awakenings is not affected.
In humans, it has hypnotic activity without noticeable
changes in the power density of NREM sleep, unlike ben-
zodiazepine receptor agonists which alter NREM sleep
EEG. Thus sleep induction by dual antagonists is sim-
ilar to spontaneous sleep in this manner (Bettica et al.,
2012; Scammell & Winrow, 2011). SB-649868 enhances
REM sleep propensity by increasing REM sleep dura-
tion and reducing REM latency.
MK-6096, a potent, reversible, orally bioavailable
dual orexin receptor antagonist, similar to its close ana-
logue dual orexin receptor antagonist-22, is a highly se-
lective reversible antagonist for both orexin receptors.
MK-6096 causes reductions in wakefulness and increases
in REM and NREM sleep in various species (Winrow &
Renger, 2014).
3.2 Melatonin
Melatonin (N-acetyl-5-methoxytriptamine) is a lipid
and water soluble hormone released mainly from the
pineal gland of the brain directly into capillary beds
and cerebrospinal fluid (CSF), to reach various tissues
around the body (Berra & Rizzo, 2009). Melatonin
has several functions in the body, such as regulat-
ing immunity, hormone secretion, reproductive and
circadian rhythms, and sleep regulation (Dubocovich,
2007). Foetuses and new-borns obtain melatonin from
placental blood and breast milk respectively. Cyc-
lic melatonin secretion increases in 9–12 week old in-
fants, with nocturnal levels peaking in children of less
than five years, and a gradual decrease of melatonin
synthesis then occurs with further aging (Zhdanova,
Lynch & Wurtman, 1997). Although the melatonin pro-
file changes amongst individuals, in a healthy person
the timing, amplitude and profile remain constant over
several weeks with no recognizable difference between
genders, when weight is accounted for (Klerman, Ger-
shengorn, Duffy & Kronauer, 2002).
The process by which melatonin induces sleep is un-
clear. Melatonin can improve sleep quality by decreas-
ing sleep onset latency and sleep fragmentation while
increasing sleep efficiency. Melatonin may increase total
sleep duration by 12.8 minutes (Brzezinski et al., 2005;
Koch et al., 2009). It also appears to involve a phase-
shift of the circadian rhythm, a reduced core body tem-
perature and/or a direct action on somnogenic struc-
tures with the central nervous system (CNS) (Buscemi
et al., 2005; Rajaratnam, Dijk, Middleton, Stone &
Arendt, 2003). Reports have shown that day-time secre-
tion of melatonin correlates with the onset of nocturnal
sleepiness. This is re-enforced by the fact that the sleep-
wake cycle in infants stabilizes at three months of age,
which is the same time when the melatonin nocturnal
peak becomes highest and there is consolidation of noc-
turnal sleep. Furthermore, sleep efficacy decreases with
age as does melatonin secretion (Zhdanova et al., 1997).
Exogenous melatonin can be given to patients suffer-
ing from primary insomnia to prolong sleep, improve
sleep efficiency, improve functional performance, and
provide patients with better sleep quality. Normal sleep
onset latency is 15–20 minutes, with 30 minutes being
characteristic of insomnia. Exogenous melatonin can
shorten sleep onset latency by four minutes and im-
proves sleep efficiency by 2.2%. Although these are not
clinically significant, patients on treatment with exogen-
ous melatonin reported better sleep quality. Exogenous
melatonin also increased endogenous melatonin levels
during the evening and night, which coincides with in-
creased sleepiness leading to improved daytime function
and alertness (Koch et al., 2009). Exogenous melatonin
appears to be relatively safe, with headache, nausea,
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dizziness and drowsiness as the only reported side-effects
during three months of use (Buscemi et al., 2005). How-
ever, the safety of longer use has not been assessed.
Melatonin acts on melatonin receptors MT1 and
MT2 (Moore, 2007) that are high-affinity G-protein
coupled receptors which can be expressed by the SCN
(Dubocovich, 2007). By acting on MT1 and MT2 re-
ceptors, melatonin regulates the amplitude and phase
of circadian oscillations. Melatonin is a chronobiotic as
it adjusts the phase of the circadian clock and helps to
entrain the light-dark cycle with the external light-day
cycle (Hardeland, 2013).
In response to melatonin, the MT1 receptor is
associated with the acute suppression of SCN (Liu
et al., 1997), causing the inhibition of the pituit-
ary adenylate cyclase activating polypeptide (PACAP)-
mediated-CREB-phosphorylation, which in turn inhib-
its neuronal firing within the SCN, thus promoting sleep.
When melatonin binds to MT2, there is phase-shifting
of the neuronal firing rate of the SCN, with a resultant
phase shift of sleep onset (Dubocovich, 2007).
Activation leading to desensitization can occur dur-
ing low day-time levels of melatonin due to prolonged
exposure to the hormone. Oral doses of melatonin lar-
ger than 1 mg will result in supra-physiological plasma
melatonin levels that can cause an increase in the ex-
pression of MT1 receptors whilst decreasing the affinity
and function. However, there is no internalization of
MT1 receptors despite significant desensitization. MT2
receptors, when exposed to supra-physiological or pro-
longed physiological levels of melatonin, are desensit-
ized and internalised, affecting the phase-shift effect of
MT2. The potency of exogenous melatonin plateaus
after 1 mg. MT2 recovers through protein synthesis after
physiological desensitization within eight hours. Recov-
ery after supra-physiological levels takes longer. De-
sensitisation after supra-physiological concentrations is
counterproductive when treating circadian rhythm sleep
disorders (Dubocovich, 2007; Wassmer, Ross & White-
house, 2000).
MT1 and MT2 receptor agonists such as ramelteon
and agomelatine are high-affinity but non-selective.
Ramelteon, a tricyclic synthetic melatonin analogue
is FDA-approved for insomnia with sleep onset diffi-
culty. It has a much stronger affinity to MT1 re-
ceptor than melatonin and is highly selective for the
melatonin receptors. It is a chronobiotic and hypnotic
and promotes both sleep initiation and maintenance,
with few next-day effects, withdrawal symptoms or re-
bound insomnia (Dubocovich, 2007; Pandi-Perumal et
al., 2007). Agomelatine, an acetamide naphthalene ana-
logue of melatonin, has high affinity receptor agonist for
MT1and MT2 receptors, causing circadian rhythm reg-
ulation. Agomelatine is also a 5-HT2C receptor antag-
onist resulting in an anti-depressant effect. Thus, MT1
and MT2 receptor agonists can be used to mimic the
effects of endogenous melatonin (Priyadarshini, Rai &
Shewede, 2015).
3.3 The Genetic Component
As with many diseases, insomnia has a significant ge-
netic predisposition. A good understanding of the aeti-
ology of insomnia contributes greatly to the understand-
ing of the disease, as well as aiding future advances in
research.
Monozygotic twins have a higher concordance rate
than dizygotic twins for sleep duration, sleep onset,
and EEG spectrum (Ambrosius et al., 2008; Sehgal &
Mignot, 2011). There are a 0.47 and 0.15 correlations
between monozygotic and dizygotic twins respectively,
with an estimated heritability of 57% for insomnia, and
38% for sleepiness. There is a correlation between in-
somnia and sleepiness, as well as insomnia with obesity
within twins, indicating a common genetic influence in
those phenotypes.
3.4 Single Nucleotide Polymorphisms
Only a few rare sleep disorders, such as fatal familial in-
somnia, narcolepsy with cataplexy, and restless legs syn-
drome have been directly linked to single gene defects.
In general, sleep disorders are caused by several muta-
tions and single nucleotide polymorphisms which have
small but accumulative effects (Seugnet et al., 2009).
Although genome wide association studies have not
identified single nucleotide polymorphisms (SNPs) that
reach the genome-wide significance threshold, plaus-
ible association has been observed with several candid-
ate genes. A link has been identified between short
sleep duration and SNPs in the neuropeptide S receptor
1 (NPSR1 ), CACNA1C and the ABCC9 gene. The
neuropeptide S receptor and its ligand NPS together
with histamine and orexin are implicated in the reg-
ulation of the wake/sleep cycle. The identified SNP
rs324981 in the NPSR1 gene that is related to bedtime
and presents a short sleep duration phenotype, is the ho-
mozygous T/T genotype (Asn107 to Ile107 substitution)
(Spada et al., 2014). Groups of SNPs in the third in-
tron of the CACNAC1C gene are associated with sleep
latency and sleep quality (Byrne et al., 2013). Not-
ably, this gene encodes a voltage-gated calcium channel
subunit that is also down-regulated in bipolar disorder
and diabetes. Individuals homozygous for an intronic
variant of the ABCC9 gene also exhibit short sleep dur-
ation. SUR2, the protein product of the ABCC9 gene
has been identified as the regulatory subunit of plasma
membrane potassium channel implicated in the regula-
tion of energy metabolism (Allebrandt et al., 2013).
A study comparing 1,439 Korean insomniacs with
7,280 controls identified two significant SNPs found in
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intronic regions within the ROR genes and the PLCB1
gene (phospholipase C beta). ROR genes participate in
neurite growth and synapse formation, with 16 and 14
SNPs in ROR1 and ROR2 respectively. The PLCB1
gene functions via calcium signalling. However, the
ROR1 SNPs s were more strongly associated with fe-
male insomniacs while the PLCB1 SNPs were associ-
ated more with males. PLCB1 and ROR1 maintain
open chromatin structure in the human pancreas via
the binding sites PAX6 and CTCF, therefore it was con-
cluded that SNPs in these genes may play a role in both
circadian and metabolic phenotypes in insomniacs (Ban,
Kim, Seo, Kang & Choi, 2011).
3.5 CLOCK Genes
Polymorphisms of the ubiquitous circadian clock genes
involved in sleep correlate with insomnia, disease chron-
icity, psychiatric conditions, and age of onset of bipolar
disorder (Takahashi, Hong, Ko & McDearmon, 2008).
The C allele of clock ck, caused by a T3111C/rs1801260
SNP at the 3’ non-translated region of chromosome
4q12, is associated with evening preference in North-
American populations, delayed sleep onset and de-
creased sleep duration. It is correlated with initial in-
somnia in individuals with major depressive disorder,
as well as night-long insomnia in those suffering from
bipolar disorder. These groups show a decreased need
of sleep throughout their lifetime and experience more
sleep disturbance with a higher recurrence of initial,
middle and early insomnia in homozygotes for the C
variants. The clock gene polymorphism may be respons-
ible for sleep dysregulation in patients with psychiatric
disorders; however, the 3111C clock polymorphism is
not correlated with a psychiatric disorder (Katzenberg
et al., 1998; Serretti et al., 2010; Voinescu, Thome &
Orasan, 2009). The incidence rate for the genotype has
been shown to be similar to that found in normal people
and a similar phenotype shown has also been demon-
strated in a normal sample of adults (Katzenberg et al.,
1998).
The circadian clock mechanism in the suprachias-
matic nucleus (SCN) and peripheral tissues involves
transcriptional-translational feedback control of core
clock components (Ko & Takahashi, 2006). Neur-
onal PAS domain protein 2 (NPAS2) is a paralogue of
CLOCK and a circadian rhythm regulator (DeBruyne,
Weaver & Reppert, 2007; Takahashi et al., 2008).
CLOCK-BMAL1, a transcription-activator complex, in-
creases the transcription of Per (Period) and Cry
(Cryptochrome). When PER:CRY heterodimers enter
the nucleus, they inhibit their own transcription by
suppressing BMAL1 and CLOCK/NPAS2 transcription
systems. PER:CRY heterodimers are degraded dur-
ing the night, allowing CLOCK/NPAS2 and BMAL1
to activate another cycle of transcription. This forms
a primary negative-feedback loop that lasts approxim-
ately 24 h (Ko & Takahashi, 2006; Takahashi et al.,
2008). The ubiquitination-directed degradation of CRY
is controlled by the opposing effects of the two ubiquitin
E3 ligase complexes FBXL3 and FBXL21, the balance
of which determines the length of the circadian period
in mice. FBXL3 degrades CRY in the nucleus, however,
FBXL21 forms an SCF ubiquitin ligase complex which
antagonises the E3 ligase activity of FBLX3 to protect
CRY from degradation in the nucleus. Furthermore,
FBXL21 forms an SCF E3 ligase complex to promote
CRY degradation within the cytoplasm. The balance of
these competing E3 ligases which cause CRY degrada-
tion will then determine the length of the circadian clock
(Yoo et al., 2013).
In Drosophila, Casein kinase 1 delta and epsilon phos-
phorylate PER1/2 and CRY1/2 in the late afternoon
and night as they accumulate, targeting them for de-
gradation by the ubiquitin-proteasome pathway. Muta-
tions in Csnk1e and Csnk1d cause shorter circadian
rhythms in mammals. The 178C missense mutation in
Csnk1e causes a tau mutant in hamster, with a 20 hour
(h) circadian period. Tau mutation does this by hy-
perphosophorylating PER, thus destabilizing by mak-
ing it a target for ubiquitination by β-TrCP and pro-
teasomes. Past-time (Psttm) mutation has also been
shown to shorten the circadian period by destabilizing
CRY proteins. β-TrCP1 and FBXL3E3 ubiquitin lig-
ase complexes respectively target PER and CRY for de-
gradation. Mutations in Fbxl3 lead to long circadian
rhythms by stabilizing CRY, and thus reducing its ubi-
quitination (Ko & Takahashi, 2006; Takahashi et al.,
2008; Yoo et al., 2013).
In a secondary feedback loop, CLOCK-BMAL1 tar-
gets directly Rev-erbα, a nuclear hormone receptor,
which suppresses the transcription of Bmal1. CLOCK-
BMAL1 increases the level of ROR that in turn activates
Bmal1 (Takahashi et al., 2008). RORα and Rev-erbα
compete to bind to the Bmal1 promoter via retinoic acid
related orphan receptor response elements (ROREs) (Ko
& Takahashi, 2006).
CLOCK has histone acetyltransferase activity and
acetylates BMAL1 on lysine 537. This, and lysine 9
and 14 of Histone H3, can be deacetylated by histone
deacetylase sirtuin 1 (SIRT1), which is expressed cyc-
lically. It controls gene expression by its interaction
with CLOCK-BMAL1 and deacetylation and degrada-
tion of Per2 (Takahashi et al., 2008). The T2434C poly-
morphism in the C allele of Per1 correlates with morn-
ing preference and disruptions in sleep timing (Carpen,
von Schantz, Smits, Skene & Archer, 2006). Variable-
number tandem repeats (VNTRs) cause a shorter al-
lele, Per34, which correlates to evening preference and
a longer allele, Per35, which correlates to morning pref-
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Figure 1: Transcriptional-Translational Feedback Loops Regulating the Circadian Clock Genes.
erence (Voinescu et al., 2009).
Circadian oscillations continue when one gene is
mutated in either the PER or CRY families. However, if
two or more mutations occur within these protein fam-
ilies, arrhythmicity results. The roles of mutated clock
genes cannot be fully compensated by the other normal
family. In mice, Per1-/- and Per2-/- cause a reduction
of circadian rhythm by 0.5–1.0 h and 1.5 h respectively.
Cry1-/- and Cry2-/- cause a reduction and addition of
1 h to the circadian rhythm respectively. Deficiency of
CRY1 and CRY2 increases NREM sleep episodes and a
lack of compensatory mechanisms of sleep deprivation.
Bmal-/- causes loss of circadian rhythms, weight loss,
infertility and shortened life expectancy. It is associ-
ated with increased sleep duration and fragmentation.
Clock-/- has different effects depending on which tis-
sues are affected. Clock-/- increases the overall levels
of Per1 in the liver and decreases it in the SCN (Ko &
Takahashi, 2006). CLOCK deficiency in mice results in
a 2 h loss of sleep. BMAL deficiency and Cry1/Cry2
double knockout both result in increased sleep duration
(Carpen et al., 2006; Laposky et al., 2005; Wisor et al.,
2002).
A homozygous dominant-negative antimorphic Clock
allele mutation (Clock∆19/∆19) causes a long circa-
dian rhythm, with loss of rhythm on prolonged con-
stant darkness. Per2 is produced rhythmically in liver
and muscle with this mutation, however, it is decreased
in kidney and heart. This results in a reduction of
sleep duration in mice. CLOCK-deficient mice however,
still produce normal molecular rhythms, implying that
CLOCK-BMAL1 is not necessarily essential in initiating
rhythms (Ko & Takahashi, 2006).
DEC2 is a transcription factor associated with re-
duced sleep (Ban et al., 2011). It represses CLOCK-
BMAL1 activity and mutations in mice causing in-
creased wakefulness (Sehgal & Mignot, 2011). In fact,
a point mutation in Dec2 causes reduced sleep duration
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in human. Sleep onset occurs at a usual time, however,
waking occurs earlier (He et al., 2009).
4 Conclusion
Despite considerable research to determine the import-
ance of sleep quality and duration, it has been diffi-
cult to draw clear conclusions regarding the aetiology
insomnia as many studies focus on sleep disturbance as
a secondary consequence to other disorders such as car-
diovascular disease or respiratory disease. It is uncer-
tain whether studies which focus on participants with
reduced sleep duration are relevant in the insomniac
population as pathological or lifestyle factors could in-
fluence sleep. Furthermore, studies are dependent on
the patient feedback whose subjectivity may cause inac-
curacies. Undiagnosed conditions, especially mood dis-
orders, are difficult to rule out when recruiting parti-
cipants for primary insomnia. In fact, it was noted by
the National Institute of Health (2005) that “insomnia
usually appears in the presence of at least one disorder.
Particularly common co-morbidities are major depres-
sion, generalized anxiety, substance abuse, attention de-
ficit/hyperactivity in children, dementia, and a variety
of physical problems” (p. 11).
There were some contradictory results regarding the
effect of insomnia and cardiovascular disease as the
cause or effect relationship is not yet clear. Research-
ers noted a change in the secretion patterns of the pro-
inflammatory cytokines in participants with insomnia,
expressing different peak times and secretion patterns.
These patterns of secretions, however, have not yet been
linked with the development of cardiovascular disease it-
self.
Although many chemicals have been implanted in the
pathophysiology of primary insomnia, it remains unclear
as to its exact aetiology. Several alleles and single nuc-
leotide polymorphisms have been identified as contrib-
utors of insomnia, however, these are likely to be only
predisposing factors to insomnia, rather than causative
agents.
Numerous pharmacological agents are available
or currently being investigated such as exogenous
melatonin, melatonin receptor agonists and orexin ant-
agonists. Despite this, no specific therapy has yet been
successfully shown to control insomnia effectively whilst
having minimal side-effects and next-day effects.
There are limited studies that focus on the biochem-
ical mechanism of which insomnia affects the physiolo-
gical systems mentioned as well as the aetiology itself
of insomnia. If more research is conducted in this area,
it may be easier to interpret the data collected from
current trials. Many of the studies relied on either self-
reported insomnia severity or polysomnography record-
ings of one to four nights. A longer term study, with
adequate follow-up may provide some more insight into
the more chronic physiological effects.
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